News
We send the latest information from SMC Laboratories.
Introduction of chronic kidney disease mice models
I am writing you today to share some information on our Chronic kidney disease (CKD) models. CKD is a c…
Introduction of NASH model with high clinical correlation
Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide. Around t…
Introduction of bleomycin-induced SSc-ILD model
Today, we would like to introduce a more clinically correlative model in which skin and lung fibrosis develop …
Introduction of positive control drug for kidney fibrosis mouse model
Today, we would like to introduce an established positive control – an ALK5 inhibitor – for our Un…
Introduction of our experiences in histopathological analyses for IPF
Today, we present some new histopathological data from our bleomycin-induced pulmonary fibrosis model, which i…
Introduction of STAM™ model for pre-clinical studies for liver cancer
Today, we give you a brief introduction to our proprietary NASH-HCC model (STAM™ model). The STAM™…
Introducing our new skin disease model: Imiquimod (IMQ)-induced psoriasis model
We are pleased to announce that we have expanded our preclinical model lineup by including the “Imiquimo…
Introduction of our Primary sclerosing cholangitis (PSC) mice model
Today, I would like to give you a brief introduction into primary sclerosing cholangitis (PSC), as well as our…
Introducing our Idiopathic Pulmonary Fibrosis (IPF) mouse model
The outbreak of COVID-19 causes a lot of complications and long-term harm to the patient, especially severe pu…
Potential NASH biomarker in NASH-HCC model
We would like to introduce the data for a serological marker from our NASH model (STAM™ model). Hepatoce…